Browsing Tag
Alagille syndrome
3 posts
Mirum Pharmaceuticals (NASDAQ: MIRM) jumps 13% after VISTAS Phase 2b PSC win
Two Phase 2b wins in seven days. A pre-NDA meeting this summer. Mirum is starting to look less like a single-product rare disease story.
Ipsen gets Bylvay FDA approval for cholestatic pruritus in Alagille syndrome
The US Food and Drug Administration (FDA) has granted approval to French biopharmaceutical company Ipsen for Bylvay (odevixibat)…
Mirum Pharmaceuticals raises $120m to advance Maralixibat for rare liver diseases
Mirum Pharmaceuticals, a clinical-stage pharmaceutical company, has successfully raised $120 million in a Series A funding round to…